DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

This study is testing a new type of immune therapy called DOC1021 — made from the patient's own immune cells (dendritic cells) — in adults who have just been diagnosed with glioblastoma, the most aggressive type of brain cancer. The treatment is given after surgery and alongside standard chemotherapy and radiation. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with glioblastoma and it has been confirmed by tissue analysis - Your tumor is believed to be surgically removable, and the goal is to remove at least 70% of it - You are well enough to carry out normal activities (Karnofsky score of 70 or higher) - Your blood counts, kidney, and liver function are adequate **You may NOT be eligible if...** - Your tumor is in the lower part of the brain (infratentorial), has recurred, or has spread to the spinal fluid or outside the brain - You are pregnant or breastfeeding - You have active HIV or uncontrolled hepatitis - You have a serious autoimmune disease requiring immune-suppressing medications - You are currently in another experimental drug trial Talk to your doctor to see if this trial is right for you.